From Yahoo Finance: 2025-05-13 08:51:00

Amidst trade tensions, Senior Biotech Analyst Michael Yee notes low valuations in the sector may offer buying opportunities. Estimated 50% tariffs and -4-5% EPS impact are manageable for many biotech companies. Yee emphasizes uncertainty but suggests stocks trading at decade-low P/E multiples could rise post-uncertainty.

Amicus Therapeutics, Inc. (FOLD) stands as the fourth-best low-priced biotech stock to buy now. With a product portfolio focusing on metabolic diseases, recent licensing agreements show growth potential. Analysts bullish on FOLD, with a median price target of $5.98 implying a substantial 167.56% upside from current levels.

Hedge funds’ interest in low-priced biotech stocks highlights potential market outperformance. Amicus Therapeutics, Inc. (FOLD) ranks 4th on the list, with strategic moves in the rare disease treatment space garnering analysts’ attention. Financial terms of recent agreements suggest a well-structured yield, supporting a positive outlook on the stock.

Read more: Is Amicus Therapeutics (FOLD) the Best Low Priced Biotech Stock to Buy Now?